Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotronik/Aachen Lekton Vita DES Slated For Q4 2004 European Launch

This article was originally published in The Gray Sheet

Executive Summary

Aachen Resonance will begin a randomized trial of its Tretinoin compound on Biotronik's Lekton Motion stent system early next year under a Nov. 19 pact giving Biotronik commercialization rights

You may also be interested in...

Conor Medsystems, Biotronik DES Would Compete With Established Players

Conor Medsystems expects technological characteristics - not price - will successfully position its CoStar drug-eluting stent against offerings from Johnson & Johnson and Boston Scientific

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts